Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Comment by biggdoggon Dec 22, 2023 10:58am
74 Views
Post# 35797692

RE:RE:RE:RE:New Press Release - Voyageur Pharmaceuticals Ltd Announces Deferred Share Unit (DSU) Grant to Directors

RE:RE:RE:RE:New Press Release - Voyageur Pharmaceuticals Ltd Announces Deferred Share Unit (DSU) Grant to DirectorsI dont think management get DSU's, "DSUs are used to compensate directors of the Corporation for their annual retainers and are issued quarterly using a deemed value that is equal to the weighted average share price during that quarter."
Looks like its only for director comp. Management needs to get sales launched, or send Warrant Officer in to give them a kick in the rear end post New Year. 
They also need to go from PEA status on FC to Feasibility status under NI-43-101 regulations, this is critical too. The Board has 4-5 independent board members, I cant imagine they are getting compensated for nothing, it would be interesting to know what exactly are they doing to help move things forward.


<< Previous
Bullboard Posts
Next >>